| Randolph Hutter, MD | |
|
91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706-1940 | |
| (808) 691-3340 | |
| Not Available |
| Full Name | Randolph Hutter |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 27 Years |
| Location | 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700047339 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Queens Medical Center | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Queens University Medical Group | 2466831557 | 543 |
| The Queens Medical Center | 3476454067 | 187 |
News Archive
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs.
An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.
Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.
› Verified 2 days ago
| Entity Name | The Queens Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487693586 PECOS PAC ID: 3476454067 Enrollment ID: O20040116000366 |
News Archive
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs.
An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.
Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.
› Verified 2 days ago
| Entity Name | Queens University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891441382 PECOS PAC ID: 2466831557 Enrollment ID: O20220621000534 |
News Archive
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs.
An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.
Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Randolph Hutter, MD 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706-1940 Ph: (808) 691-3340 | Randolph Hutter, MD 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706-1940 Ph: (808) 691-3340 |
News Archive
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs.
An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.
Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.
› Verified 2 days ago
Mr. Kevin Marc Salire, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706 Phone: 808-691-3340 Fax: 808-691-3345 | |
Dr. Brian Hunter Levins Jr., M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 91-2301 Old Ft Weaver Rd, Ewa Beach, HI 96706 Phone: 808-677-2587 | |
Mrs. Aurora C Mariani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 91-2139 Fort Weaver Rd. #307, Ewa Beach, HI 96706 Phone: 808-680-0008 Fax: 808-680-0049 | |
Laverne Arabella Kia, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 912139 Fort Weaver Road, Suite 209, Ewa Beach, HI 96706 Phone: 808-671-4530 Fax: 808-676-1066 | |
Dr. Kimberly Kyle, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-691-3000 | |
Albert Lin, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 91-2141 Fort Weaver Rd, Ewa Beach, HI 96706 Phone: 808-678-7000 | |
Daniel K Chan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 91-2135 Fort Weaver Rd Fl 3, Ewa Beach, HI 96706 Phone: 808-691-3150 Fax: 808-691-3153 |